Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TBPH vs AURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: TBPH 5 – 1 AURA Matrix Metrics: TBPH 8 – 2 AURA

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas AURA carries 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. AURA 28.8/100 SELL) and 0.48β · 2% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TBPH vs AURA
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 50.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.7 · SMA20: $6.66 · SMA50: $6.54

6-Pillar Scorecard Institutional Category Breakdown (TBPH 5 – 1 AURA)

Columns: Metric · TBPH · AURA
1. Valuation Multiples TBPH
Forward P/E 13.4x N/M
Trailing P/E 16.4x N/M
PEG Ratio N/M N/M
EV / Revenue 8.5x N/M
2. Growth & Scale TBPH
Revenue Growth (YoY) -20.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $104M N/A
Market Cap $884.2M $728.6M
3. Profitability & Quality TBPH
Gross Margin 75.1% N/A
Operating Margin 8.9% 0.0%
Net Profit Margin 51.6% 0.0%
Return on Equity (ROE) 20.9% -61.7%
4. Balance Sheet & Cash Flow TBPH
Cash Generation (TTM) $11M EBITDA -$110M
Cash Flow Margin 10.6% EBITDA Mgn N/A
Net Cash / Leverage $5.58 Book/Sh · 20.9% ROE $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 55.0% (16th %ile) 160.1% (22nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity 66.2% of Rev ($69M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TBPH (8) vs AURA (2)
Institutional Metric TBPH AURA Criterion Row Edge
Market Capitalization
Scale
$884.2M $728.6M Larger Scale TBPH
Trailing P/E Ratio
Valuation
16.4x N/M Lower Multiple TBPH
Forward P/E Ratio
Valuation
13.4x N/M Lower Multiple TBPH
Revenue Growth (YoY)
Growth
-20.9% +0.0% Higher Growth AURA
Operating Margin (TTM)
Profitability
8.9% 0.0% Higher Margin TBPH
Net Profit Margin
Profitability
51.6% 0.0% Higher Margin TBPH
Return on Equity (ROE)
Capital Efficiency
20.9% -61.7% Higher ROE TBPH
52-Week Range Position
Momentum
50% ($13–$21) 52% ($5–$10) Stronger Trend AURA
Beta / 30D Volatility
Risk Regime
0.48β · 2% Vol 0.92β · 75% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite TBPH
Trailing 12M Revenue (USD)
Operating Scale
$104M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$11M EBITDA ($5.58 Book/Sh · 20.9% ROE) -$110M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TBPH +23.92 pp
TBPH: +0.12% · AURA: -23.8%
3M Horizon TBPH +13.1 pp
TBPH: -1.39% · AURA: -14.49%
6M Horizon TBPH +18.9 pp
TBPH: +14.3% · AURA: -4.6%
1Y Horizon AURA +13.99 pp
TBPH: -5.13% · AURA: +8.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TBPH vs AURA. Trailing 12-month operating profitability (TBPH 8.9% vs AURA 0.0%) and valuation multiples (TBPH 13.4x vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x
AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TBPH vs AURA Key Questions & Quantitative Answers

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas AURA carries 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. AURA 28.8/100 SELL) and 0.48β · 2% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

TBPH leads the Growth & Scale pillar: TBPH posts -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin), compared with AURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TBPH generates $104M in USD-normalized revenue versus N/A for AURA. In operating R&D and SG&A reinvestment, TBPH deploys 66.2% of Rev ($69M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AURA.

TBPH screens cheaper on headline valuation multiples. TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin), whereas AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TBPH (20.9% ROE) versus AURA (-61.7% ROE) capital efficiency.

In options market volatility and institutional positioning, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk). By comparison, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.